Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Anne J Kugler & Michael L Thiman. (2018) Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data. Diabetes, Metabolic Syndrome and Obesity 11, pages 187-197.
Read now
Read now
Marc S. Rendell. (2017) The safety of albiglutide for the treatment of type 2 diabetes. Expert Opinion on Drug Safety 16:9, pages 1089-1097.
Read now
Read now
Ambika Amblee. (2016) Mode of administration of dulaglutide: implications for treatment adherence. Patient Preference and Adherence 10, pages 975-982.
Read now
Read now
Marc S. Rendell. (2016) Albiglutide: a unique GLP-1 receptor agonist. Expert Opinion on Biological Therapy 16:12, pages 1557-1569.
Read now
Read now
Articles from other publishers (9)
Hoda E. Mohamad, Merna A. Abdelhady, Sara M. Abdel Aal & Rania A. Elrashidy. (2022) Dulaglutide mitigates high dietary fructose-induced renal fibrosis in rats through suppressing epithelial-mesenchymal transition mediated by GSK-3β/TGF-β1/Smad3 signaling pathways. Life Sciences 309, pages 120999.
Crossref
Crossref
Dia Advani, Sudhanshu Sharma, Rahul Tripathi, Rohan Gupta, Asmita Jaiswal, Rashmi K. Ambasta & Pravir Kumar. 2021. Mitochondrial Dysfunction and Nanotherapeutics. Mitochondrial Dysfunction and Nanotherapeutics
91
137
.
Yozo Takehisa & Hiroshi Bando. (2020) Elderly Diabetic Patients with Effective Add-on Therapy of Dulaglutide as a GLP-1 Receptor Analogue (GLP-1 RA). Edelweiss Journal of Biomedical Research and Review, pages 31-35.
Crossref
Crossref
Shirakawa M, Kanamoto Y, Nagaoka H, Honda H & Bando H. (2019) Diabetic cases controlled with low carbohydrate diet (LCD) and GLP-1 receptor agonist (GLP-1 RA). Asploro Journal of Biomedical and Clinical Case Reports 2:S1, pages 38-46.
Crossref
Crossref
Deborah A. Chon, Rachael T. Oxman, Rashmi S. Mullur & Jane Eileen Weinreb. 2019. Endocrine Disorders in Kidney Disease. Endocrine Disorders in Kidney Disease
49
74
.
Helena W. Rodbard. (2018) The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. Diabetes Technology & Therapeutics 20:S2, pages S2-33-S2-41.
Crossref
Crossref
Keith C. Ferdinand, Fady T. Botros, Charles M. Atisso & Philip T. Sager. (2016) Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology 15:1.
Crossref
Crossref
Prachi Gupta, Manju Bala, Sanjeev Gupta, Anita Dua, Rajesh Dabur, Elisha Injeti & Ashwani Mittal. (2016) Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs—A mechanistic revisit to understand their mode of action. Pharmacological Research 113, pages 636-674.
Crossref
Crossref
M. M. Smits, L. Tonneijck, M. H. A. Muskiet, M. H. H. Kramer, D. L. Cahen & D. H. van Raalte. (2016) Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes, Obesity and Metabolism 18:3, pages 224-235.
Crossref
Crossref